89 results about "New Bone Formations" patented technology

The present invention provides an efficient gene delivery system using Adeno-Associated Viral (AAV) vector in gene therapy. Furthermore, the invention provides a combined AAV and Adenovirus (Adv) cocktail gene delivery system which is even more efficient in in vivo gene delivery and expression without eliciting any significant immune responses in an immunocompetent subject. In particular, the invention provides a therapeutic agent and methods for preventing, treating, managing, or ameliorating various diseases and disorders including, but not limited to, bone diseases, by delivering Bone Morphogenetic Protein 2 (BMP-2) for new bone formation via gene therapy using said system. The invention provides a nucleic acid molecule comprising an AVV vector and a promoter operably linked to a sequence encoding BMP-2; and a nucleic acid molecule comprising an Adv vector and a promoter operably linked to a sequence encoding BMP-2, as well as vectors and host cells comprising said nucleic acid molecules, respectively.

The invention discloses a tissue engineered bone compound which comprises porous perforated between aperture artificial bone bracket and mesenchymal stem cells implanted in hole and transfected with vascular endothelial growth factor gene. The invention also discloses the application of the tissue engineered bone compound as material for bone defect repair. The inventive tissue engineered bone compound can make seed cell exert osteogenesis, express and secrete VEGF, thereby promoting vasal formation and growth, providing material basis for new bone formation, in favor of neogenesis of vascularized tissue engineered bone tissue, improving effect for repairing bone defect.

Alloys of titanium with 20-22 at. % niobium and 12-13 at. % zirconium. The alloys are prepared by mechanical alloying of elemental powders and densification by spark plasma sintering. The alloys have a nano-scaled, equiaxed granular structure, a microhardness of at least 650 HV and a modulus of 90-140 GPa. The inventive alloy is corrosion resistant, biocompatible, and is of a higher wear resistance and durability compared to the Ti-6Al-4V alloy. The bioactive surface of the inventive nanostructured alloy promotes a higher protein adsorption that stimulates new bone formation than other titanium-based alloys. These alloys are suitable for various biomedical and dental applications.

The invention discloses a porous composite biological material containing multiple active ions and a preparation method thereof, relating to the technical filed of production of medical materials. The porous composite biological material is a triple compound containing multiple active ions and calcium phosphate-silicate-calcium carbonate, and is composed of a porous ceramic structure main body containing active ions A and calcium phosphate-calcium carbonate and a phosphate-silicate cement coating, wherein both phosphate and silicate in the phosphate-silicate cement coating contain active ions B and calcium; and the phosphate-silicate cement coating accounts for 5-60% (mass percent) of the micropore structure main body. According to the invention, the exquisite three-dimensional intercommunication micropore structure of cuttlebone having extremely high porosity is kept, has excellent bone conductibility and favorable degradability, and can be subjected to stepped degradation; the release of the active ions and beneficial elements can be regulated and controlled; and the overall degradation rate of the material can be regulated according to different new bone formation requirements.

Improved compositions comprising a mixture of particulate bone growth material and polymeric carrier are provided. The particulate is preferably porous, resorbable, anorganic bone material. The polymeric carrier can be light-cured to form a cross-linked, biodegradable hydrogel. In one version, the bone growth material is a synthetic peptide bound to anorganic bone matrix particles and the carrier is methacrylated sodium hyaluronate (MHy) or methacrylated hydroxyethylcellulose (MHEC). The composition is particularly suitable for repairing defective dental and orthopedic bone tissue. The particulate and hydrogel carrier are biodegradable so the composition can be replaced by new bone formation over time.

The invention relates to a preparation method of an antigen-removing biological bone. The preparation method comprises bone block pretreatment, partial deproteinization treatment, irradiation treatment, organic matter removal, EDC/NHS crosslinking and drying sterilization. Bone particles are treated by irradiation to make proteins degenerated, then a mixed solution of a surface active agent and hydrogen peroxide is used for treating the irradiated bone particles, followed by a hypochlorite solution and a hydrogen peroxide solution are used for treating, and the deproteinized biological bone is obtained after ethylene oxide sterilization. The prepared bone material has a three-dimensional porous structure, has good capillary adsorption, can adsorb osteoblasts and protein factors after being implanted in bodies, and induces new bone formation; the bone material allows antigen components to be effectively removed, retains a part of collagen, and has better biocompatibility; and the bone material allows hydroxy apatite to have the crystallization degree of lower than 15% and exist in a weak crystallization morphology, has no other crystal phases, allows the carbonate content to be 4%-6%, has relatively high mechanical strength and good degradation, and is suitable for a repairing operation material for non load-bearing part bone coloboma.

The invention discloses a bone cement of a bio-based polyurethane composite degradable material, which is composed of a solid phase powder material and a liquid phase composite, wherein the solid phase powder mainly comprises inorganic powder and/or a prepolymerized organic filler insoluble in a polyurethane monomer, doped reinforcing fibers and other functional powders. The liquid phase compositemainly comprises a bio-based polyurethane prepolymer and a liquid phase monomer diluent. The liquid phase composite is slowly added to the solid phase powder material, and the materials are sufficiently mixed and solidified to form the bone cement. The bone cement can completely replace the bone cement such as PMMA, calcium phosphate and calcium sulfate on the market, and has excellent biologicalactivity and the ability to promote new bone formation. After injecting into the human bone defect site, the mechanical properties are excellent, the polymerization reaction produces less heat, and the bone cement degradation rate is matched with the new bone formation inducing speed, and the autologous bone in-situ regeneration is achieved to ensure stable and controllable bone increment.

The invention discloses an injectable bone repair material with a controllable magnesium ion release behavior and a preparation method of the material, relates to the field of injectable bone repair materials, and aims at developing an injectable microsphere cell carrier loaded with magnesium-containing inorganic components. Different from common microcarriers such as sephadex in a large-scale cell culture technology, microphseres are prepared from aliphatic polyester with adjustable rate of biodegradation and can be injected into defect parts in a human body together with cells performing adhesive growth on the surfaces by serving as cell carriers, and along with tissue regeneration, a polyester microsphere support is gradually degraded and absorbed by an organism and gives way to regenerated tissue. The magnesium-containing inorganic components are introduced in the microcarriers, by selecting different magnesium-containing inorganic components and changing the proportion and intakeof the magnesium-containing inorganic matter in the microspheres, the release behavior of magnesium ions is regulated and controlled, and then the bioactive microsphere type bone repair material withthe excellent osteogenesis promoting capacity is developed by means of the biological effect of the magnesium ions in the new bone formation process.

The invention relates to a gel material which comprises 3-80 wt% of sucrose acetate isobutyrate colloidal particle, 0.1-30 wt% of pharmaceutical active component, 0-60 wt% of assistant and the balance of water. The gel material is applicable to promoting bone healing and new bone formation in tooth cavities after implementation of tooth extraction. The bone healing is wound healing after implementation of tooth extraction; and the new bone formation is new bone formation in a tooth implantation process. The gel material can also be used for temporary sealing after cavity preparation and during dental pulp disease treatment in the tooth disease treatment process.

The invention discloses bioactive polypeptide for promoting osteogenic growth and a preparation method thereof. The amino sequence is any one of Ac-(X1-X2-X1-X2-X1-X3-X1-X3)n-GG-ALKRQGRTLYGF-CONH2, Ac-(X1-X2-X1-X2-X1-X3-X1-X3)n-GG-DGRGDSVAYG-CONH2 and Ac-(X1-X2-X1-X2-X1-X3-X1-X3)n-G-PRGDSGYRGDS-CONH2; and the polypeptide is synthesized by a solid-phase synthesis method. Through the bioactive polypeptide disclosed by the invention, the nutritional substances, bioactive molecules and oxygen can reach the cultivated cells, the biocompatibility is good, the restriction on source is broken through, and the osteogenic growth peptide can obviously promote osteogenic differentiation and new bone formation.

The invention discloses an Sr and Mg doped amorphous apatite material and crystalline apatite material, belonging to the field of biomedical materials. The different concentrations of Sr and Mg doped amorphous apatite material is rapidly prepared by using Ca(NO3)2, Mg(NO3)2, Sr(NO3)2, (NH4)2HPO4 and ammonia-water as raw materials and then is transformed to the different concentrations of Sr and Mg doped nano calcium-deficient hydroxyapatite or nano tricalcium phosphate material through heat treatment. Compared with traditional hydroxyapatite crystalline materials, the amorphous material has higher solubility. The amorphous apatite material and the crystalline apatite material have the beneficial effects that after Sr and Mg doping, Sr can achieve the effects of promoting new bone formation, reducing reabsorption of bone, adjusting calcium metabolism and reducing the activity of osteoclast, and Mg can achieve the effects of affecting early growth of bone substances and regulating growth and remodelling of the bone substances; therefore the synthesized amorphous apatite and the crystallized product thereof have important roles in the fields of bone repair and bone transplantation.

A bone regeneration material uses polyphosphoric acid and/or a polyphosphate together with a biocompatible material, a filler for cosmetic surgery, or a bone morphogenetic protein, to expedite new bone formation and shorten healing time or restoration in the treatment of bone fractures or damage.

Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided.

The invention relates to an aquagel material which comprises 3-80 wt% of colloidal particle containing lactic acid polymer, 0.1-40 wt% of pharmaceutical active component, 0-80 wt% of assistant and the balance of water. The aquagel material is applicable to promoting bone healing and new bone formation in tooth cavities after implementation of tooth extraction. The bone healing is wound healing after implementation of tooth extraction; and the new bone formation is new bone formation in a tooth implantation process. The aquagel material can also be used for temporary sealing after cavity preparation and during dental pulp disease treatment in the tooth disease treatment process.

The invention provides methods for treating or preventing bone degenerative disorders. The disorders treated or prevented include, for example, osteopenia, osteomalacia, osteoporosis, osteomyeloma, osteodystrophy, Paget's disease, osteogenesis imprerfecta, and bone degenerative disorders associated with chronic renal disease, hyperparathyroidism, high levels of endogenous thyrotropin, and long-term use of corticosteroids. The disclosed therapeutic methods include administering to a mammal a TSHR agonist in an amount effective to: (1) treat or prevent a bone degenerative disorder; (2) slow bone deterioration; (3) restore lost bone; (4) stimulate new bone formation; and/or (5) maintain bone mass and/or bone quality. TSHR agonists such as thyrotropin and its modified forms are provided along with other compounds, such as anti-resorptive agent and bone metabolic agents.

The invention relates to a mineralized collagen based skull repairing device and a manufacturing method thereof. The mineralized collagen based skull repairing device is made of a mineralized collagen/PCL (polycaprolactone) composite material; and the appearance of the repairing device comprises a spherical segment cap at the upper part and a cylindrical plug at the lower part. A separation mold and a secondary pouring technology are adopted during preparation of the mineralized collagen based skull repairing device, and the product defect caused by air residue at the blind end of the mold is overcome. The skull repairing device made of the mineralized collagen/ PCL composite material has excellent osteogenic activity, the material is gradually and passively degraded under the creeping substitution action of cells, and growth of new bones can be guided at the skull defect part. A degradation product of the composite material is neutral, acidic materials causing aseptic inflammation cannot be generated, and new bone formation isn't affected; and through composition of PCL, the skull repairing device has excellent elasticity and toughness besides enough crush resistance and bending strength, and the repairing requirement of a skull of a human body is met.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a Chinese patent medicine for treating femoral head necrosis and a preparation method of the Chinese patent medicine. The Chinese patent medicine is prepared from the following raw materials in parts by weight: 5-10 parts of ligustrazine, 5-10 parts of ossotide, 6-8 parts of pseudo-ginseng, 6-8 parts of teasel root, 2-5 parts of calcined pyritum, 6-8 parts of drynaria rhizome, 3-6 parts of root of red-rooted salvia, 3-6 parts of eucommia ulmoides, 3-6 parts of radix achyranthis bidentatae, 2-5 parts of ground beetle, 3-6 parts of prepared rehmannia root, 3-6 parts of angelica sinensis, 2-5 parts of peach kernel, 2-5 parts of cartialgenous and 2-5 parts of liquorice. The preparation method comprises the following steps: weighing the raw materials according to the parts by weight; crushing into fine powder, filtering by an 80-100mesh sieve and then enclosing powder into a hollow capsule, wherein each capsule is 0.6-0.7g; bottling and sealing. The traditional Chinese medicine components disclosed by the invention can assist ligustrazine and ossotide in easing pain, reducing swelling, simulating osteoblast proliferation and promoting new bone formation when playing roles in removing blood stasis, connecting muscles and bones, stopping bleeding and promoting granulation; components of the traditional Chinese medicines and the western medicines cooperatively act; the treatment period for femoral head necrosis is short; and recovery is thorough.

This document provides methods and materials involved in promoting new bone formation for the treatment of medical conditions such as osteoporosis, bone defects, bone injury (e.g., fractures) implant ingrowth, and joint/spine fusions. For example, methods and materials for using sulforaphane and/or EZH2 polypeptide inhibitors (e.g., GSK126 or UNC1999) to treat osteoporosis, bone fractures and defects, implant ingrowth, and joint fusions are provided.

The invention discloses a porous bone repair stent material which is prepared by cross-linking reaction of human-like collagen and sub-nanometer hydroxyapatite under the action of cross-linking agents, wherein the cross-linking agents are agaricus bisporus polyphenol oxidase, the weight ratio of the human-like collagen to the sub-nanometer hydroxyapatite is 1:(2-5), and the dosage of the agaricusbisporus polyphenol oxidase is 400-1000U/g. In addition, the invention further discloses a preparation method of the porous bone repair stent material. The agaricus bisporus polyphenol oxidase servesas the cross-linking agents, the sub-nanometer hydroxyapatite prepared by mineralization with the human-like collagen serving as a template serves as an inorganic phase, the human-like collagen servesas an organic phase, and lecithin and cell growth factors are added. According to the porous bone repair stent material prepared by an enzyme cross-linking technology, cross-linking agent residues donot need to be removed, the stent material has good biocompatibility, and the stent material can be reused as a new bone formation raw material after degradation.

The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P₁/S1P₃ activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase microvascular remodeling. S1P₃ expression on marrow-derived cells was essential for this remodeling. Concurrent systemic S1P₃ and CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) with the ability to engraft and repopulate blood cells. Pre-treatment of donor HSCs with FTY720 increased homing toward SDF-1 and improved engraftment in marrow. FTY720-coated bone allografts coupled with systemic administration of VPC01091 enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand. The results show that S1P is a very powerful role player in pharmacological marrow-derived stem cell mobilization and recruitment.